Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia

Haematologica

Volumn 91, Issue 9, 2006, Pages 1281-1282

  Samuelson, Jan ^a   Mutschler, Manuel ^b   Birgegård, Gunnar ^c   Gram Hansen, Poul ^d   Björkholm, Magnus ^e   Pahl, Heike L ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

interferon; Essential thrombocythemia; JAK2; Polycythemia vera

Indexed keywords

JANUS KINASE 2; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; REMISSION; THROMBOCYTHEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; INTERFERON ALFA-2B; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; THROMBOCYTHEMIA, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 33748804929     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Samuelsson J, Hasselbakh H, Bruserud O, Temerinac S, Brandberg Y, Merup M, et al. A phase II trial of pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia. Feasibility, clinical and biological effects and impact on quality of life. Cancer 2006;106:2397-405.
2. Gugliotta L, Bulgarelli S, Tieghi A, Asioli S, Gardini G, Sabattini E, et al. PVSG and WHO bone marrow evaluation in 90 essential thrombocythemia patients treated with PEG interferon α-2-b. Preliminary results. Haematologica 2005;90Suppl 2:264a[abstract].
3. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 2005;90:1333-8.
4. Messora C, Bensi L, Vechi A, Giacobbi F, Temperani P, Berini M, et al. Cytogenetic conversion m a case of polycythaemia vera treated with interferon-α. Br J Haematol 1994;86:402-4.
5. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-e response to erythropoietin. Blood 2003;101:3294-301.
6. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-8.
7. Klippel S, Strunck E, Temerinac S, Bench AJ, Memhardt G, Mohr U, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003;102:3569-74.
8. Goerttler PS, Steimle C, Marz F, Johansson PL, Andreasson B, Griesshammer M, et al. The JAK2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-4.
9. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon α. Blood 2006;107:3339-41.
10. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with interferon α-2a. Blood 2006;[E-pub ahead of print].